Payers Worry About High Costs, Low Evidence for Gene Therapies

So far, the FDA has approved eight cell and gene therapies, but the agency is expected to approve several more medications in those classes in the next few years. That has caused concern for payers because such medications have high costs and limited clinical evidence, according to speakers who participated in an Avalere Health webinar on May 25.

As such, the federal government, PBMs, health insurers and other payers are testing innovative ways to reimburse hospitals, providers and pharmaceutical companies for administering cell and gene therapies.

© 2022 MMIT
Freelance Reporter

Freelance Reporter Freelance Reporter

Related Posts

scientists-in-lab-working-wiht-test-tubes-and-science-overlays
December 16

Biomarker Testing Is Not Keeping Up With Drug Innovations

Read More
coin-stack-money-financial-business-growth-men-background-is-signing-documents
July 8

Employers Have Variety of Approaches for High-Cost Drugs

Read More
post-default-image
July 8

Cell/Gene Therapy Pay Models Face Reporting, Policy Barriers

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today